BMS pumps $400 million into Irish facility expansion

22 February 2024

bristol_myers_squibb_ireland_artist_large

US pharma major Bristol Myers Squibb (NYSE: BMS) has announced the investment of $400 million into a company facility in Dublin, Ireland (pictured above, as envisaged).

The investment at the Cruiserath site is for the build and design of a sterile drug product facility, which will support the manufacturing and supply of existing medicines as well as serve as a launch excellence site for pipeline assets.

This will be BMS’ first European sterile drug product facility for biologics manufacturing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK